UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JUNE 2020
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
An der Goldgrube 12 D-55131 Mainz Germany
+49 6131-9084-0
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On June 26, 2020, BioNTech SE (the “Company”) conducted its Annual General Meeting (AGM) for shareholders in Munich, Germany. The shareholder voting results overview are attached hereto as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
BioNTech SE |
|
|
|
|
|
|
|
|
By: |
/s/ Dr. Sierk Poetting |
|
|
Name: Dr. Sierk Poetting |
|
|
Title: Chief Financial Officer |
|
|
|
Date: June 26, 2020
Exhibit |
Description of Exhibit |
|
|
99.1 |
Annual General Meeting in Munich, Germany, June 26, 2020 Voting Results. |
Exhibit 99.1
BioNTech SE, Mainz, Germany |
|
Annual General Meeting in Munich, Germany, 26 June 2020 |
Voting results - Overview - Only the German version is binding
Agenda Item 2 |
Approval of the actions of the Management Board - accepted |
||||
152,033,174 |
|
Number of shares for which valid votes were cast (= 63.826 % of the registered share capital) |
|||
152,015,170 |
|
Yes votes |
|
99.988 % of the valid votes cast |
|
18,004 |
|
No votes |
|
0.012 % of the valid votes cast |
|
Approval of the actions of the Supervisory Board - accepted |
|||||
|
Number of shares for which valid votes were cast (= 30.864 % of the registered share capital) |
||||
73,497,269 |
|
Yes votes |
|
99.974 % of the valid votes cast |
|
19,439 |
|
No votes |
|
0.026 % of the valid votes cast |
|
Agenda Item 4 |
Appointment of the auditor for the 2020 financial year - accepted |
||||
195,931,883 |
|
Number of shares for which valid votes were cast (= 82.256 % of the registered share capital) |
|||
195,927,278 |
|
Yes votes |
|
99.998 % of the valid votes cast |
|
4,605 |
|
No votes |
|
0.002 % of the valid votes cast |
|
Agenda Item 5 |
Amendment of the authorization to issue stock options - accepted |
||||
195,518,062 |
|
Number of shares for which valid votes were cast (= 82.082 % of the registered share capital) |
|||
195,449,670 |
|
Yes votes |
|
99.965 % of the valid votes cast |
|
68,392 |
|
No votes |
|
0.035 % of the valid votes cast |
|
Agenda Item 6 |
Expansion of options to exclude subscription rights for authorised capital - accepted |
||||
195,507,877 |
|
Number of shares for which valid votes were cast (= 82.078 % of the registered share capital) |
|||
195,492,290 |
|
Yes votes |
|
99.992 % of the valid votes cast |
|
15,587 |
|
No votes |
|
0.008 % of the valid votes cast |
|
Agenda Item 7 |
Amendments to the Articles of Association in connection with the invitation to and conduct of general meetings - accepted |
||||
195,487,103 |
|
Number of shares for which valid votes were cast (= 82.069 % of the registered share capital) |
|||
193,271,471 |
|
Yes votes |
|
98.867 % of the valid votes cast |
|
2,215,632 |
|
No votes |
|
1.133 % of the valid votes cast |
|
Agenda Item 8a |
Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Small Molecules GmbH as dependent company - accepted |
||||
195,511,012 |
|
Number of shares for which valid votes were cast (= 82.079 % of the registered share capital) |
|||
195,505,708 |
|
Yes votes |
|
99.997 % of the valid votes cast |
|
5,304 |
|
No votes |
|
0.003 % of the valid votes cast |
|
Agenda Item 8b |
Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech IVAC GmbH as de-pendent company - accepted |
||||
195,510,926 |
|
Number of shares for which valid votes were cast (= 82.079 % of the registered share capital) |
|||
195,505,442 |
|
Yes votes |
|
99.997 % of the valid votes cast |
|
5,484 |
|
No votes |
|
0.003 % of the valid votes cast |
BioNTech SE, Mainz, Germany |
|
Annual General Meeting in Munich, Germany, 26 June 2020 |
Voting results - Overview - Only the German version is binding
Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Real Estate Holding GmbH as dependent company - accepted |
|||||
195,510,844 |
|
Number of shares for which valid votes were cast (= 82.079 % of the registered share capital) |
|||
195,504,260 |
|
Yes votes |
|
99.997 % of the valid votes cast |
|
6,584 |
|
No votes |
|
0.003 % of the valid votes cast |
|
Agenda Item 8d |
Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company - accepted |
||||
195,511,026 |
|
Number of shares for which valid votes were cast (= 82.079 % of the registered share capital) |
|||
195,503,722 |
|
Yes votes |
|
99.996 % of the valid votes cast |
|
7,304 |
|
No votes |
|
0.004 % of the valid votes cast |
|
Agenda Item 8e |
Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Cell & Gene Therapies GmbH as dependent company - accepted |
||||
195,511,435 |
|
Number of shares for which valid votes were cast (= 82.079 % of the registered share capital) |
|||
195,504,552 |
|
Yes votes |
|
99.996 % of the valid votes cast |
|
6,883 |
|
No votes |
|
0.004 % of the valid votes cast |